Day: July 10, 2023

Global Multi-effects Processor Market is Expected to Record a CAGR of 5.9% From 2023 To 2032 – Latest Industry Insights by Esticast Research & Consulting

Written by Customer Service on July 10, 2023. Posted in Dividend Reports And Estimates.

According to experts from Esticast Research, the growth of the market is being propelled by technological advancements, particularly the adoption of digital signal processing (DSP) technology. Esticast Research, July 10, 2023 (GLOBE NEWSWIRE) — Pune, India 10th July 2023, Multi-effects Processor Market -Growth Factors and Dynamics The Multi-effects Processor market is segmented By type (Reverb Effect, Delay Effect, and Others) and By Application (Beginner and Professional), By Region, And Segment Forecasts, 2023 – 2032Attributes ValueMulti-effects Processor Market Expected Value (2023) USD 270.55 millionMulti-effects Processor Market Forecast Value (2032) USD 337.86 millionMulti-effects Processor Market Expected CAGR (2023 to 2032) 5.9%Click Here to Access a Free Sample Report ON Global Multi-Effects Processor Market https://www.esticastresearch.com/request-a-sample/37526The...

Panbela Announces Preliminary Safety Analysis for ASPIRE Trial

Written by Customer Service on July 10, 2023. Posted in Public Companies.

MMINNEAPOLIS, July 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase III ASPIRE clinical trial for patients with untreated metastatic pancreatic ductal adenocarcinoma has completed its pre-specified review of safety data for treated patients in the trial. The DSMB has recommended that the study continue without modification. The ASPIRE Trial is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. “We are pleased that no safety concerns were identified and the DSMB’s...

Xometry Further Expands Offerings On Its AI-Powered Marketplace

Written by Customer Service on July 10, 2023. Posted in Public Companies.

Xometry Instant Quoting Engine® Now Supports Inserts, Multi-Part Assemblies And Expanded Sheet-Cutting Processes Enhancements Further Accelerate Xometry’s Assembly Production Work Proprietary AI Technology Learns From Every Interaction, Enabling Xometry To Continuously Evaluate, Build And Roll Out New Products Delivering Instant Pricing And Lead Times For Ever-Expansive Universe Of PartsNORTH BETHESDA, Md., July 10, 2023 (GLOBE NEWSWIRE) — Xometry, the global AI-driven marketplace connecting enterprise buyers with suppliers of manufacturing services, today announced the continued expansion of its AI-powered Xometry Instant Quoting Engine® to include instant-quoting of inserts, multi-part assemblies, and expanded sheet-cutting processes. The enhanced features allow buyers to instantly get pricing and lead times on CNC, sheet...

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

Written by Customer Service on July 10, 2023. Posted in Public Companies.

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies. ROCKVILLE, Md. and PHILADELPHIA, July 10, 2023 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and to support innovative, cell-based research, and Vittoria Biotherapeutics (Vittoria), a leading edge, gene-edited cell therapeutics company with novel platform technologies poised to develop a pipeline of highly differentiated cellular therapies for both oncology and immunology indications, today announced the signing of a strategic platform license...

AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Written by Customer Service on July 10, 2023. Posted in Public Companies.

Preliminary Ampligen data demonstrates potential to be an effective treatment option for post-COVID conditions Enrollment expected to be completed in Q4 2023 OCALA, Fla., July 10, 2023 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced it has enrolled and dosed the first subject in the company’s Phase 2 study evaluating Ampligen® as a potential therapeutic for people with post-COVID conditions (“AMP-518”). This important study milestone follows on the heels of the company having recently opened multiple clinical study sites and having screened numerous subjects. Study screening is ongoing and AIM expects to dose additional new subjects in the coming weeks. For more information about AMP-518, please visit ClinicalTrials.gov and reference identifier NCT05592418. AIM Chief Executive Officer Thomas...

BIO-key Customers in Florida and Illinois Migrate Their Identity and Access Management to the Cloud with PortalGuard® IDaaS

Written by Customer Service on July 10, 2023. Posted in Public Companies.

WALL, N.J., July 10, 2023 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB), announced that existing customers West Aurora School District 129 in Aurora, IL and Gulf Coast State College in Panama City, FL are migrating to BIO-key’s PortalGuard® IDaaS cloud-based identity management solution, a significant step in modernizing their IAM capabilities. By adopting IDaaS, West Aurora and Gulf Coast can centralize and streamline their identity management processes while taking advantage of cloud scalability, flexibility, and security while providing an enhanced user experience – all with improved administrative capabilities. In today’s digital landscape, where secure access...

TerrAscend Reaches Four Dispensary Cap in Maryland with Closing of Herbiculture Acquisition

Written by Customer Service on July 10, 2023. Posted in Mergers And Acquisitions.

Acquisition expected to be immediately accretive on an EBITDA and cashflow basis TORONTO, July 10, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis company, today announced the closing of its previously announced acquisition of Herbiculture Inc. (d/b/a “Herbiculture”), a medical dispensary in Maryland. With this transaction, TerrAscend has reached the four dispensary cap in the state. With the recent launch of adult-use sales in Maryland on July 1, 2023, the Company believes that Herbiculture is well positioned to achieve substantial sales and profit growth. This transaction is expected to be immediately accretive to TerrAscend on an EBITDA and cashflow basis. Located in an approximately 3,100 square foot location in Burtonsville, Herbiculture...

Voyager Therapeutics Announces Appointment of Jacquelyn Fahey Sandell as Chief Legal Officer

Written by Customer Service on July 10, 2023. Posted in Public Companies.

CAMBRIDGE, Mass., July 10, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced the appointment of Jacquelyn Fahey Sandell as Chief Legal Officer (CLO). Fahey Sandell brings more than 25 years of legal experience spanning in-house roles at multiple biotechnology and pharmaceutical companies. She most recently served as CLO, Corporate Secretary, and Compliance Officer of Jounce Therapeutics, Inc. “Jacqui’s breadth of expertise across securities, business development, regulatory, intellectual property, and multiple other legal disciplines makes her a strong addition to the growing Voyager team,” said Al Sandrock, M.D., Ph.D., Chief Executive Officer of Voyager. “In addition to her impressive subject matter expertise,...

Connect Biopharma Presented Additional Data from its Atopic Dermatitis Pivotal Trial in China at the 2023 World Congress of Dermatology

Written by Customer Service on July 10, 2023. Posted in Public Companies.

Four poster presentations provided detailed and new data on the achievement of primary and secondary endpoints, improvements in investigator-rated outcomes, and improvements in patient reported outcomes from the initial 16-week treatment period with rademikibart (formerly known as CBP-201) in patients with moderate-to-severe atopic dermatitis (AD) in the pivotal CN002 trial in ChinaSAN DIEGO and TAICANG, China, July 10, 2023 (GLOBE NEWSWIRE) — Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced it presented four posters at the 25th World Congress of Dermatology being held...

KAMO Power Deploys Infinera’s XTM Series to Upgrade Its Rural Broadband Network

Written by Customer Service on July 10, 2023. Posted in Public Companies.

SAN JOSE, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Infinera (NASDAQ: INFN) announced today that KAMO Electric Cooperative, Inc. (KAMO Power) is deploying Infinera’s XTM Series on its 2,700-route-mile rural network to serve its 17 member cooperatives across northeast Oklahoma and southwest Missouri. The deployment upgrades KAMO Power’s network, providing the cooperative with an open optical network that delivers high-capacity, reliable, and secure transport services. KAMO Power is a Generation and Transmission (G&T) cooperative and one of the largest of its kind, providing its members safe, cost-effective, and reliable power through its high-voltage transmission network and communications system. In addition to serving the region as the largest power source, KAMO Power’s cooperative members rely on its robust open optical network...

Day: July 10, 2023

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice